Product Details
| Product Name:
RMC-9805 |
CAS No.:
2922732-54-3 |
| Purity:
99.41% |
Supply Ability:
10g |
| Release date:
2025/07/16 |
Product Introduction
Bioactivity
| Name | RMC-9805 |
| Description | RMC-9805 is a novel, mutant-selective, covalent and oral KRASG12D (ON) inhibitor. A stable and high affinity triple complex is formed between RMC-9805, KRASG12D, and cyclophilin A, which inhibits signal transduction downstream of KRASG12D (ON) by disrupting its interaction with downstream effectors. RMC-9805 can induce cell apoptosis and promote tumor regression in preclinical KRASG12D tumor models. With rich experience in compound synthesis, we can provide fast customized synthesis services for this product according to your research needs. |
| In vitro | METHODS: eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells were treated with RMC-9805 (100 nM) for 48 hours, and cytokine levels were measured using a cytokine array. Cell surface expression was detected by flow cytometry.
RESULTS: CXCL1 and GM-CSF were reduced in eCT26 (KRASG12D/G12D) and KPCY 6499c4 (KRASG12D/+) cells, while PD-L1 and PVR were reduced; CXCL10 and CCL17 increased, while MHC-I and MHC-II increased. [2] |
| In vivo | METHODS: To detect in vivo anti-tumor activity, RMC-9805 (100 mg/kg) was orally administered to eCT26 (KRASG12D/G12D) xenograft tumor mice once a day for 4-8 days.
RESULTS: RMC-9805 exhibits anti-tumor activity in the KRAS G12D xenograft model. [2] |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (85.58 mM), Sonication is recommended.
|
| Keywords | KRAS G12D |
| Inhibitors Related | Adagrasib | (S)-AMG-510 | BI-2493 | ARS-1323 | ARS-1323-alkyne | Kras4B G12D-IN-1 | BI-3406 | MRTX1133 | MRTX-1257 | Sotorasib | RMC-7977 | GNE-9815 |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2641998-63-0
$162.00 / 1mg
-
CAS:2172651-73-7
$56.00 / 1mg
-
CAS:2765081-21-6
$58.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$782.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-20 |
|
|
$0.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-30 |
United States